Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FANCA S1088F |
| Therapy | Olaparib |
| Indication/Tumor Type | prostate cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FANCA S1088F | prostate cancer | predicted - sensitive | Olaparib | Preclinical - Pdx | Actionable | In a preclinical study, overexpression of FANCA S1088F in FANCA-null cells derived from Fanconi anemia patients resulted in increased sensitivity to Lynparza (olaparib) in culture, and a patient-derived xenograft (PDX) model of prostate cancer harboring germline FANCA S1088F demonstrated enhanced sensitivity to Lynparza (olaparib) treatment (PMID: 28864460). | 28864460 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (28864460) | A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. | Full reference... |